Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases
Condition: Breast Cancer
MeSH terms: Breast Diseases
Study type: Observational

Summary: 
      The aim of our study is to investigate the potential role of the CYP2D6*4 polymorphism in
      breast cancer and furthermore to assess the role of oxidative stress, antioxidant capacity
      and ferretin in pathogenesis of breast cancer in different CYP2D6*4 genotypes
    

Detailed description: 
      Breast cancer is the most common malignancy among women and the second highest cause of
      cancer death. Nevertheless most of the breast cancer is sporadic with no family history of
      the disease, Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver,
      pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. Data support
      that increased formation of reactive oxygen species (ROS) may play an important role in
      carcinogenesis Numerous in vitro experiments show that ROS damages DNA, inducing premutagenic
      modifications of nucleotides and promoting oxidation of proteins and lipid per oxidation The
      aim of our study is to investigate the potential role of the CYP2D6*4 polymorphism in breast
      cancer and furthermore to assess the role of oxidative stress, antioxidant capacity and
      ferretin in pathogenesis of breast cancer in different CYP2D6*4 genotypes.patients and
      methods : This study included 31 women admitted to the general surgery department, Mansoura
      University Hospital. group I consists of 15 women with benign breast lesion, group II
      composed of 16 women with cancer breast and 13 healthy women with matched age and clinically
      free were taken as a control group. DNA extraction and genotyping of cytochrome P450-2D6*4
      gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma
      was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma
      antioxidant capacity and plasma ferretin level.Results homozygous genotype of 2D6*4 represent
      56.25 %( 9/16) of breast cancer group with lower wild type (31.25%-5/16), while it represent
      33.3 %( 5/15) of begnine breast lesion group and 15.3(2/13) of the control group. Where the
      wild type represent the majority of cases (61.15%-8/13) in the control group and 46.6%-7/15)
      in the begnine breast lesion group.

      statistically significant increase in plasma ferretin and MDA mean levels in breast cancer
      group than begnine breast lesion and the control groups .Also, there is an increase in plasma
      total antioxidant activity in breast cancer group than the control group with nonstatistical
      difference between the breast cancer and the benign breast lesion groups .

      Conclusion CYP2D6*4 genotype polymorphism interacting with plasma malondialdehyde (MDA)
      oxidative stress and plasma ferretin level may have a role in the pathogenesis of breast
      cancer
    

Intervention name(s): pcr and serum markers for breast cancer
Intervention type(s): Genetic
Intervention description(s): DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
Observational model: Case-Control
Time perspective: Other
Keywords: breast cancer; cytochrome 450; CYP2D6*4; Ferritin; oxidative stress; cancer; cancer breast